Advertisement
Advertisement
PLUR
Pluri Inc. Common Stock
3.31
USDSponsored
+0.27
+8.69%
Mar 25, 15:02 UTC -4
Closed
After-Market
3.32
+0.01
+0.27%
PLUR Earnings Reports
Positive Surprise Ratio
PLUR beat 19 of 30 last estimates.
63%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
$668.10K
/-$0.67
Implied change from Q2 26 (Revenue/ EPS)
+237.42%
/-5.63%
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Pluri Inc. Common Stock earnings per share and revenue
On Feb 12, 2026, PLUR reported earnings of -0.71 USD per share (EPS) for Q2 26, missing the estimate of -0.66 USD, resulting in a -7.09% surprise. Revenue reached 198.00 thousand, compared to an expected 650.76 thousand, with a -69.57% difference. The market reacted with a +0.28% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.67 USD, with revenue projected to reach 668.10 thousand USD, implying an decrease of -5.63% EPS, and increase of 237.42% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were Pluri Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Pluri Inc. Common Stock reported EPS of -$0.71, missing estimates by -7.09%, and revenue of $198.00K, -69.57% below expectations.
How did the market react to Pluri Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 0.28%, changed from $3.55 before the earnings release to $3.56 the day after.
When is Pluri Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Pluri Inc. Common Stock's next earnings report?
Based on 3
analysts, Pluri Inc. Common Stock is expected to report EPS of -$0.67 and revenue of $668.10K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement